ADMA Biologics, Inc.ADMANASDAQ
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank26
3Y CAGR-44.6%
5Y CAGR-36.6%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
-44.6%/yr
vs +26.5%/yr prior
5Y CAGR
-36.6%/yr
Recent deceleration
Acceleration
-71.1pp
Decelerating
Percentile
P26
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 3.68% |
| Q3 2025 | 10.03% |
| Q2 2025 | 6.26% |
| Q1 2025 | -2.34% |
| Q4 2024 | -1.91% |
| Q3 2024 | 11.80% |
| Q2 2024 | 30.92% |
| Q1 2024 | 10.79% |
| Q4 2023 | 9.85% |
| Q3 2023 | 11.90% |
| Q2 2023 | 5.64% |
| Q1 2023 | 13.87% |
| Q4 2022 | 21.64% |
| Q3 2022 | 21.19% |
| Q2 2022 | 16.50% |
| Q1 2022 | 10.31% |
| Q4 2021 | 27.57% |
| Q3 2021 | 15.98% |
| Q2 2021 | 11.10% |
| Q1 2021 | 14.99% |
| Q4 2020 | 35.81% |
| Q3 2020 | 31.96% |
| Q2 2020 | -23.65% |
| Q1 2020 | -15.26% |
| Q4 2019 | 66.66% |
| Q3 2019 | 10.08% |
| Q2 2019 | 85.94% |
| Q1 2019 | -13.01% |
| Q4 2018 | -4.11% |
| Q3 2018 | -9.15% |
| Q2 2018 | 15.20% |
| Q1 2018 | -66.32% |
| Q4 2017 | 153.79% |
| Q3 2017 | 39.12% |
| Q2 2017 | 29.31% |
| Q1 2017 | -21.00% |
| Q4 2016 | 13.26% |
| Q3 2016 | 29.32% |
| Q2 2016 | 6.96% |
| Q1 2016 | -15.46% |